Wugen
Fierce Biotech Fundraising Tracker ’25: CHARM attracts $80M; Wugen reels in $115M
CHARM Therapeutics; AI drug design; menin inhibitor; acute myeloid leukemia (AML); Series B funding; venture capital; biotech fundraising; Wugen; NVIDIA; drug development
Wugen Nabs $115M for Pivotal Study of Allogeneic CAR-T
Wugen; CAR-T; allogeneic; off-the-shelf therapy; fratricide-resistant; funding; pivotal trial; T-cell malignancies